Skip to content

 

Consolidated segment reporting

Consolidated segment reporting by business segment

Download(XLS, 39 KB)
Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate Fresenius Group
€ in millions 20211 20202 Growth 20213 20204 Growth 20215 2020 Growth 20215 2020 Growth 20216 20207 Growth 2021 2020 Growth
Sales 17,619 17,859 -1% 7,193 6,976 3% 10,891 9,818 11% 2,297 2,068 11% -480 -444 -8% 37,520 36,277 3%
thereof contribution to consolidated sales 17,570 17,819 -1% 7,126 6,916 3% 10,862 9,798 11% 1,960 1,742 13% 2 2 0% 37,520 36,277 3%
thereof intercompany sales 49 40 23% 67 60 12% 29 20 45% 337 326 3% -482 -446 -8% – –  
contribution to consolidated sales 47% 49%   19% 19%   29% 27%   5% 5%   0% 0%   100% 100%  
EBITDA 3,501 4,090 -14% 1,601 1,490 7% 1,600 1,470 9% 191 113 69% -68 -63 -8% 6,825 7,100 -4%
Depreciation and amortization 1,586 1,591 0% 448 395 13% 473 445 6% 90 84 7% 70 200 -65% 2,667 2,715 -2%
EBIT 1,915 2,499 -23% 1,153 1,095 5% 1,127 1,025 10% 101 29 -- -138 -263 48% 4,158 4,385 -5%
Net interest -280 -368 24% -58 -82 29% -184 -180 -2% -10 -20 50% 26 -9 -- -506 -659 23%
Income taxes -367 -501 27% -259 -239 -8% -199 -171 -16% -20 -4 -- 12 12 0% -833 -903 8%
Net income attributable to shareholders of Fresenius SE & Co. KGaA 1,018 1,359 -25% 778 730 7% 728 666 9% 67 2 -- -773 -1,050 26% 1,818 1,707 7%
                                     
Operating cash flow 2,489 4,233 -41% 1,203 1,143 5% 1,204 1,149 5% 151 78 94% 31 -54 157% 5,078 6,549 -22%
Cash flow before acquisitions and dividends 1,660 3,197 -48% 659 450 46% 637 609 5% 72 2 -- 33 -75 144% 3,061 4,183 -27%
                                     
Total assets 34,367 31,689 8% 14,698 13,591 8% 20,891 19,241 9% 2,795 2,716 3% -789 -591 -34% 71,962 66,646 8%
Debt 13,320 12,380 8% 4,159 4,181 -1% 8,059 7,472 8% 721 686 5% 896 1,194 -25% 27,155 25,913 5%
Other operating liabilities 6,199 6,192 0% 3,250 3,225 1% 3,176 2,585 23% 994 933 7% 385 385 0% 14,004 13,320 5%
Capital expenditure, gross 854 1,052 -19% 532 687 -23% 568 541 5% 80 95 -16% -2 23 -109% 2,032 2,398 -15%
Acquisitions, gross / investments 628 407 55% 1 31 -97% 453 459 -1% 1 6 -83% 2 -1 -- 1,085 902 20%
                                     
Research and development expenses 221 194 14% 595 553 8% 3 2 50% – –   -14 2 -- 805 751 7%
Employees (per capita on balance sheet date) 130,251 133,129 -2% 41,397 40,519 2% 123,484 116,952 6% 19,721 19,414 2% 1,225 1,255 -2% 316,078 311,269 2%
                                     
Key figures                                    
EBITDA margin 19.9% 22.9%   22.3% 21.4%   14.7% 15.0%   8.3% 5.5%         18.3%3 19.7%4  
EBIT margin 10.9% 14.0%   16.0% 15.7%   10.3% 10.4%   4.4% 1.4%         11.3%3 12.7%8  
Depreciation and amortization in % of sales 9.0% 8.9%   6.2% 5.7%   4.3% 4.5%   3.9% 4.1%         7.1% 7.5%  
Operating cash flow in % of sales 14.1% 23.7%   16.7% 16.4%   11.1% 11.7%   6.6% 3.8%         13.5% 18.1%  
ROOA 6.2% 8.2%   9.4% 9.2%   5.9% 5.7%   4.3% 1.3%         6.5%9 7.3%10  
1 Before costs related to FME25 program   
2 Before impairment of goodwill at FMC Latin America 
3 Before expenses associated with the Fresenius cost and efficiency program and revaluations of biosimilars contingent purchase price liabilities
4 Before revaluations of biosimilars contingent purchase price liabilities 
5 Before expenses associated with the Fresenius cost and efficiency program
 6 After expenses associated with the Fresenius cost and efficiency program and revaluations of biosimilars contingent purchase price liabilities
7 After revaluations of biosimilars contingent purchase price liabilities and impairment of goodwill at FMC Latin America
8 Before revaluations of biosimilars contingent purchase price liabilities and impairment of goodwill at FMC Latin America
 9 The underlying pro forma EBIT does not include expenses associated with the Fresenius cost and efficiency program and revaluations of biosimilars contingent purchase price liabilities.
 10 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities and impairment of goodwill at FMC Latin America.
The consolidated segment reporting by business segment is an integral part of the notes. 

Consolidated segment reporting by region

Download(XLS, 36 KB)
  Europe North America Asia-Pacific
€ in millions 2021 2020 Growth 2021 2020 Growth 2021 2020 Growth
Sales 16,888 15,813 7% 14,363 14,801 -3% 3,938 3,705 6%
contribution to consolidated sales 45% 44%   38% 41%   11% 10%  
EBIT 873 883 -1% 2,198 2,766 -21% 861 758 14%
Depreciation and amortization 1,073 1,003 7% 1,268 1,235 3% 227 196 16%
                   
Total assets 32,346 29,489 10% 31,787 29,771 7% 5,451 5,018 9%
Capital expenditure, gross 1,154 1,253 -8% 635 861 -26% 141 190 -26%
Acquisitions, gross / investments 401 199 102% 652 262 149% 13 28 -54%
                   
Employees (per capita on balance sheet date) 180,122 174,835 3% 76,740 75,837 1% 27,145 27,805 -2%

Consolidated segment reporting by region

Download(XLS, 36 KB)
  Latin America Africa Fresenius Group
€ in millions 2021 2020 Growth 2021 2020 Growth 2021 2020 Growth
Sales 1,830 1,566 17% 501 392 28% 37,520 36,277 3%
contribution to consolidated sales 5% 4%   1% 1%   100% 100%  
EBIT 176 -60 -- 50 38 32% 4,158 4,385 -5%
Depreciation and amortization 88 270 -67% 11 11 0% 2,667 2,715 -2%
                   
Total assets 2,082 2,056 1% 296 312 -5% 71,962 66,646 8%
Capital expenditure, gross 86 86 0% 16 8 100% 2,032 2,398 -15%
Acquisitions, gross / investments 18 413 -96% 1 –   1,085 902 20%
                   
Employees (per capita on balance sheet date) 30,192 30,871 -2% 1,879 1,921 -2% 316,078 311,269 2%
The consolidated segment reporting by region is an integral part of the notes.